MedTrace Logo

Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes

NCT02503943 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-07-21

No results posted yet for this study

Summary

Obesity is one of the characteristics of type 2 diabetes mellitus. Most of the obese diabetes patients are combined with dyslipidemia or hypertension. The clustering of diabetes, obesity, hypertension and dyslipidemia increases the risk of cardiovascular events for patients. GLP-1 (glucagon like peptide-1) is a kind of incretin discovered in recent years. It was reported that beside its hypoglycemic and losing weight effects, activator of GLP-1 receptor could decrease blood pressure and improve lipid metabolism. Therefore, activation of GLP-1 receptor may become a new comprehensive treatment strategies for improving glucose and lipid metabolism, blood pressure level and cardiovascular complication. But, it is lack of evidence-based medicine proof on the relationship between GLP-1 and blood pressure or serum lipid. So, investigators designed a prospective, randomized, open-label, active control study, and try to evaluate the effects of activator of GLP-1 receptor (liraglutide) on lowering blood pressure, improving vascular function and lipid metabolism in overweight or obese type 2 diabetic patients with masked hypertension.

Conditions

Interventions

DRUG

"Liraglutide" and "Mitiglinide"

"Liraglutide"(1.2mg/d) and "Mitiglinide" (50mg, 3/d)

DRUG

"Metformin" and "Mitiglinide"

"Metformin"(500mg, 3/d) and "Mitiglinide"(50mg, 3/d)

DRUG

"Mitiglinide"

"Mitiglinide" (50mg, 3/d)

Sponsors & Collaborators

  • Third Affiliated Hospital of Third Military Medical University

    lead OTHER

Principal Investigators

  • Zhiming Zhu, MD, PHD · The third hospital affiliated to the Third Military Medical University. China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02503943 on ClinicalTrials.gov